Acute myeloid leukemia (AML) is an aggressive malignant disease defined by abnormal expansion of myeloid blasts. Despite recent advances in understanding AML pathogenesis and identifying their molecular subtypes based on somatic mutations, AML is still characterized by poor outcomes, with a 5-year survival rate of only 30%-40%, the majority of the patients dying due to AML relapse. Leukemia stem cells (LSC) are considered to be at the root of chemotherapeutic resistance and AML relapse. Although numerous studies have tried to better characterize LSCs in terms of surface and molecular markers, a specific marker of LSC has not been found, and still the most universally accepted phenotypic signature remains the surface antigens CD34+CD38-that is shared with normal hematopoietic stem cells. Animal models provides the means to investigate the factors responsible for leukemic transformation, the intrinsic differences between secondary post-myeloproliferative neoplasm AML and de novo AML, especially the signaling pathways involved in inflammation and hematopoiesis. However, AML proved to be one of the hematological malignancies that is difficult to engraft even in the most immunodeficient mice strains, and numerous ongoing attempts are focused to develop "humanized mice" that can support the engraftment of LSC. This present review is aiming to inCristina Mambet, Mihaela Chivu-Economescu, Lilia Matei, Laura Georgiana Necula, Denisa Laura Dragu, Coralia Bleotu, Carmen Cristina Diaconu troduce the field of AML pathogenesis and the concept of LSC, to present the current knowledge on leukemic blasts surface markers and recent attempts to develop best AML animal models.
INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive cancer characterized by unrestricted proliferation of functionally immature myeloid cells. High heterogeneity and var iable expansion capacity of multiple clones within each patient [1, 2] , clinical and molecular differences between de novo and secondary AML, complicate even more treatment choices and make targeted therapy a goal yet to far to reach without using models that are able to simplify the multitude of mechanisms that might be involved in leukemogenesis.
In the last decades, murine models become very important tools in the field of preclinical research in oncology, hematology, and immunology, providing a platform for study of tumor biology and for in vivo ev aluation of drugs in patientderived xenograft tumors (PDX). Nowadays, a large variety of immunodeficient mice strains have emerged, able to support the xen ografting and development of a complex human hem atolymphoid system. The most difficult to reproduce is the immune system and the bone marrow (BM) microenvironment, mostly because of the differences between the signaling molecules responsible for the maturation of different hematopoietic cell populations [3] . Although the field of animal models has experienced a recent exponential growth through the development of 58 WJSC|www.wjgnet.com
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null immunodeficiency mice, AML remains one of the hematologic malignancies difficult to engraft into the existing strains of mice due to the lack of a proper BM niche and absence of specific human growth factors and supporting stromal cells [4] . As a result several attempts were made to develop "humanized mice" that can better support myeloid leukemiainitiating stem cells xenografting.
This review is aiming to introduce AML pathogenesis and the concept of leukemic stem cells and the current most advanced strategies to overcome challenges in obtaining AML murine models.
AML PATHOGENESIS AND THE
CONCEPT OF LEUKEMIC STEM CELLS
AML is a heterogeneous hematopoietic malignancy de fined by clonal expansion of abnormally differentiated or undifferentiated myeloid progenitors (blasts) that accumulate in the BM and impair hematopoiesis, lea ding to multilineage cytopenias [5, 6] . Blasts can also migrate from BM into peripheral blood and infiltrate other tissues [5] . AML can be divided in 3 categories taking into acc ount their clinical ontogeny: Secondary AML (sAML) occurred after leukemic transformation of a preexi sting myelodysplastic syndrome or myeloproliferative neoplasm, therapyrelated AML (tAML) developed in patients that received leukemogenic chemotherapy for antecedent nonmyeloid malignancies and de novo AML generated in the absence of a previous stem cell disorder or a therapeutic exposure to cytotoxic drugs [7] . Despite recent progress in understanding AML pat hogenesis and recognizing molecular subtypes of AML that have prognostic impact, AML is still characterized by poor outcomes, with a 5year survival rate of only 30%40%. The dismal prognosis is mainly related to high rate of relapse and refractory disease [2, 8] . Patients with sAML and tAML display even a much worse pro gnosis, the median overall survival rate being 7 months. Notably, somatic mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 proved to be highly specific for sAML. They are acquired early in leukemogenesis and tend to persist during clonal remissions [7] . Increasing evidence support the concept that a mi nor population of stem cells, named leukemia stem cells (LSCs), is responsible for leukemia initiation, disease progression and relapse, as well as drug resistance [9] . AML was among the first diseases in which the exis tence of cancer stem cells was documented using xe nograft animal models [10] . LSCs are derived from transformed hematopoietic stem cells (HSCs) or downstream committed proge nitors [11] . They are able to initiate the disease after transplantation into immunodeficient mice and are ch aracterized by both unlimited selfrenewal potential in ducing disease in serial transplantation and capacity to partially differentiate into nonLSC blasts that lack self renewal properties and possibility of engraftment [12] . Although LSCs and nonLSC blasts harbor a common set of mutations there are epigenetic differences bet ween them. A predominant hypomethylation of HOXA gene cluster that has been involved in leukemogenesis represents a main feature of LSCs [13] . It is thought that, similarly to normal hematopoietic system, AML displays a hierarchical organization with LSCs on the top, being able to generate the whole population of AML blast cells [10] . Signaling pathways that control selfrenewal of HSCs, such as Wnt/βcatenin, PI3K/Akt/mTOR, or Hedgehog, are also involved in LSC survival and expansion and can serve as therapeutic targets to facilitate eradication of LSCs [8, 11] . Moreover, LSCs might escape apoptosis through upregulation of NFκB or downregulation of Fas/CD95. Additionally, CXCL12CXCR4 axis promotes retaining of LSCs within the protective BM microenvironment [11] . The existence of a preleukemic stage in AML was proven by isolating from leukemia patients a population of HSCs that was found to bear some, but not all, of the mutations identified in the downstream leukemia. These preleukemic HSCs, that can be distinguished from LSCs by the surface antigen markers, TIM3 and CD99, are capable to generate bilineage engraftment in NOD.CgPrkdc 
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tm1Wjl (NSG) mice and the derived lymphoid and myeloid progeny display the same preleukemia mutations [14] . According to the currently proposed model of preleukemic clonal evolution, the first leukemiarelated mutation has to occur in a cell that possesses selfrenewal capacity or, alternatively, must confer selfrenewal properties to a more diff erentiated progenitor [15] . By singlecell analysis it was shown that during the process of leukemogenesis, the preleukemic HSCs gradually acquire somatic mutations in a nonrandom pattern [16] . Thus, in the early phases of AML evolution there is enrichment for mutations in epigenetic modifiers such as TET2, DNMT3A, IDH1/2, and ASXL1. On the other hand, mutations in genes involved in signaling pathways and proliferation, su ch as FLT3 and KRAS occur in later stages. Other le ukemogenic mutations in genes like NPM1, CEBPA, and WT1 can be found in preleukemic phase as well as in later stages [15, 16] . The preleukemic HSCs that eventually give rise to AML persist in patient samples at diagnosis and are resistant to current chemotherapy, thus representing a source of disease recurrence [17] .
LEUKEMIA-INITIATING STEM CELLS AND
BLASTS
The identification of LSCs in AML plays an important role in disease diagnosis, prognosis and AML therapy monitoring, and also represents an important step in development of targeted therapy and drug discovery [9] . Although initial studies suggested that LSCs were CD34+CD38 and did not expressed other lineage markers [1821] , later studies proved that the LSC phe notype was more complex and heterogeneous [22, 23] . At present, it is established that LSCs are characterized by increased or decreased expression of surface markers of normal myeloid precursors (CD34, CD38, CD33, CD13, CD117, and CD123), asynchronous expression of antigens determined by AML morphological subtype and by the LSC stage of differentiation (CD4, CD11b, CD14, CD15, CD36, CD61, CD64, CD71, etc.), as well as by aberrant expression of lymphoid antigens (crosslineage expression) (CD2, CD5, CD7, CD19, CD22, CD56, Tim3, etc.) [2430] . LSCs reside mainly in CD34+CD38 population, but may be present also in other cellular fractions, usually CD34+CD38+, and in some cases, in CD34 population [12, 31] . Additional markers, more specific for the advanced characterization of cellular subpopulations in AML, include: CD90 [32] , CD96 [33] , CD123 [34, 35] , CD47 [36] , CD44, Ctype lectinlike mo lecule1 (CLL1) [37] , aldehyde dehydrogenase, etc [38] . Currently, standard diagnosis and subclassification of AML integrate the study of cell morphology, gene tics/cytogenetics and multiparametric immunophe notyping. The antibody panels for surface markers used for subclassification of each AML group are showed in Figure 1 .
Methods commonly used to assess HSC properties are colonyforming cell (CFC) assay, long term culture (LTC), flow cytometry and competitive repopulation.
The CFC assay is an important tool used to evaluate the ability of the progenitor cells to proliferate and differentiate into multiple lineages. In order to produce colonies, cells are cultured in a semisolid medium, in the presence of appropriate cytokines for 714 d. Colonies are counted and characterized according to morphologic and phenotypic criteria. Although this shortterm colony assay can determine the frequencies of hematopoietic progenitor cells in analyzed populations, still, it is not able to detect more immature progenitors or HSCs/ LSCs. To overcome this limitation, the cells can be cultured for 58 wk on a stromal feeder layer that can provide a substrate and a source of cytokines and growth factors, in effort to mimic the in vivo niche con ditions [39] . The longterm cultureinitiating cells (LTCICs) can be evaluated by their capacity to generate CFCs in culture supernatant after 5 wk. This period allows CFCs present in the inoculum to terminally differentiate and the remaining CFCs may represent the progeny of LTC ICs. Subsequent limiting dilution tests can be performed to determine the LTCIC frequency [40] . Although this method facilitates the detection of more immature progenitor cells, it is time consuming and the presence of stromal cells can induce procedure variations and different outcomes [41, 42] . Competitive repopulation represents the best me thod to assess the functional abilities of immature progenitor/stem cells by serial transplants in immunoc ompromised mice. This method is based on the ability of cells that are investigated to compete with non manipulated standard cells to repopulate the BM of an irradiated recipient [43] .
MURINE MODELS -WHICH ARE THE BEST CHOICE?
Animal models are used as replacement for human bi ological niches due to ethical restrictions in the use of human tissue samples from donors. Moreover, animal models accurately recapitulate human disease and have been an important tool in advancing the understanding of human pathology, and development of preclinical therapy. Small animals, such as mice and rats, are often used as a model for various diseases because of their ease in breeding, maintenance, and manipulation. In spite of these many advantages, there are limitations due to the disparities between the murine and human biological systems. Human immune system and the BM microenvironment are the most difficult to be re produced in mouse models because of the differences in the signaling molecules responsible for the maturation of various hematopoietic cell populations [3] . As a result, many malignant hematopoietic and other hematologic disorders do not successfully engraft in conventional mice models.
AML is one of these hematologic malignancies that fail to properly graft into the existing strains of mice due to the lack of a proper BM niche, homing elements, absence of specific human growth factors and supporting stromal cells [4] . As a result, several at tempts have been made to develop murine models that reproduce with fidelity human hematopoiesis, par ticularly the development of the myeloid line.
Early attempts to increase the support for myel opoiesis involved the use of mice injected with IL3, GM CSF, SCF [44] , mice producing human TPO [45] or MISTRG mice strain which produces human tumor necrosis fac tor and IL6 [46] . These confirmed that the introduction of human genes into mice led to the production of fu nctional proteins capable of supporting engraftment and proliferation of human grafts.
The following attempts were aimed to develop next generation mouse models genetically engineered to support myeloid differentiation from human HSC. Thus, it was necessary to act at three major levels in order to induce tolerance in the murine host, provide a supportive niche, and support hematopoiesis/proliferation with appropriate growth factors and cytokines.
The first request was fulfilled by the development of mice that lacked the adaptive and innate immune compartment like NSG and NODShi.CgPrkdc at induced either the absence or the presence of an nonfunctional truncated form of the receptor subunit. The gamma chain subunit is a major component of the IL2, IL4, IL7, IL9, IL15 and IL21 receptors, and is indispensable for binding and signaling of these cytokines [47, 48] . The second condition, involved the ablation of mouse cells to create open niches for human transplanted cells. These were achieved through irradiation or depletion of mouse stroma via introducing mutations in c-Kit gene encoding for SCF receptor. SCF plays an important role in the maintenance and differentiation of HSCs [49] . The ckit mutated mice strain, known as NODB6.SCID Il2rγ / Kit (W41/W41) (NBSGW) mice, supports engraftment studies with human HSCs without prior irradiation. McIntosh et al [49] showed that in peripheral blood, the median human CD45+ count in nonirradiated NBSGW mice was similar to the count in irradiated NSG. In BM a significant increase in CD45+ was observed in non irradiated NBSGW (97%) compared to nonirradiated NSG (30%). The third constraint regarding the need for sup portive myeloid cytokines was overcome using animal models with transgenic expression of hSCF, hGMCSF and hIL3 on the NOD SCID background resulting the NSGSGM3 mouse strain [also known as NOD.Cg Prkdc scid Il2rg tm1Wj1 Tg(CMVIL3,CSF2,KITLG)/1Eav)].
Wunderlich et al [4] reported the development and use of NSGSGM3 mouse for the engraftment of normal CD34+ and AML xenografts. The results showed an improvement in the expansion of normal human myel oid cells, as well as an enhanced engraftment of primary human AML samples. They injected five samples of primary AML in sublethally irradiated NGS and NSG SGM3 mice. Only three samples from five engrafted in NSG mice, compared to five samples in NSGSGM3 mice, showing variability in the engraftment potential across the AML samples, and that NSGSGM3 strain was a better host for some subsets of AML, relative to NSG mice. Moreover, three of five samples with primary AML had higher BM engraftment level in NSGSGM3 [4] . Similar results regarding variable engraftment potential in immunodeficient mice strains were obtained by Klco et al [50] They injected blasts from six AML samples in tail vein of nonirradiated NSG and NSGSGM3. The results showed that four samples had higher BM engraftment and CD34+ expression level in NSGSGM3 than NSG mice. Finally, we can conclude that nextgeneration hum anized mouse models are able to support myeloid blast development and differentiation.
XENOGRAFT MOUSE MODELS USED FOR ACUTE MYELOID LEUKEMIA
Cell line derived xenografts
AML represents a heterogeneous disease including several subtypes which are characterized by specific fusion oncogenes as a result of chromosome abnorma lities. The fusion oncogenes in AML are associated with different clinical and laboratory characteristics, highlighting the different ways of malignant transfor mation in this disease. A study focused on the ev aluation of four important AML fusion oncogenes rep orted that MLLAF9 and NUP98HOXA9 had very similar effects in vitro on primary human CD34+ cells, resulting in erythroid hyperplasia and an obvious blockage in erythroid and myeloid maturation while AML1ETO and PMLRARA produced only modest effects on myeloid and erythroid differentiation. Moreover, MLLAF9, NUP98 HOXA9 and AML1ETO fusion oncogenes generated a significant increase in longterm proliferation and self renewal of CD34+ cells. The characterization of gene profiles determined by AML fusion oncogenes can be considered an important tool for the discovery of new potential drug targets. In this study, two different ti me patterns of gene deregulation as result of fusion of these oncogenes were observed: MLLAF9 and NUP98HOXA9, caused gene deregulation 3 d after transduction, while gene deregulation by AML1ETO and PMLRARA appeared within 6 h. Interestingly, p53 inhibitor MDM2 was upregulated by AML1ETO at 6 h suggesting that MDM2 upregulation was involved in cell transformation, being related to AML1ETO [51] . Wei et al [52] evaluated the in vitro and in vivo effects of MLL-AF9 gene fusion in human CD34+ cord blood cells using retroviral vectors. Thus, MA9 transduced ce lls became immortal and doubled in number every 23 d. The expression of CD33, CD11b, CD13, CD14 and CD15 suggested a myelomonocytic lineage. Moreover, longterm cultured MA9 cells failed to differentiate towards the erythroid or B lymphoid lineages, remaining cytokine and FLT3L dependent for growth. In nonobese diabetic/severe combined immunodeficient [NOD/SCID (NS)], NSβ2M/ (NSB2M) and NS mice, MA9 cells induced acute myeloid, lymphoid, or mixedlineage leu kemia with blast cells present in the peripheral blood, BM, spleen and liver. Gene expression profile of MLLAF9 transduced cells was similar to human AML with 11q23 translocations, Rac signaling pathway being the most affected pathway and a promising therapeutic target in MLLrearranged AML [52] . Another AML subtype with a particularly poor outcome is characterized by the t(6;9)(p22;q34) chromosome rearrangement which generates DEKNUP214 chimeric gene. Qin et al [53] developed an AML model harboring DEKNUP214, using CD34+ human hematopoietic progenitor cells and MO7e cell lines xenografted into immunocompromised mice that expressed human myeloid cell growth factors. The M07e human megakaryoblastic leukemia cell line was strictly dependent on either IL3 or GMCSF for survival; retroviral expression of this fusion gene in IL3 dependent M07e cell line induced a cytokine independence and increased colony formation ability in softagar. DEKNUP214 expression also modified the differentiation of human cord blood CD34+ progenitor cells, which expressed myeloid lineage markers (CD13+), with small subsets showing T (CD3+) and B (CD19+) cell linage markers. The obtained results suggested that DEKNUP214 was involved in leukemic transformation and differentiation of myeloid cells. In this study, CD34+ progenitor cells obtained from three different umbilical cord blood samples and transduced with chimeric DEK NUP214 were engrafted in NSGSGM3 mice strain. Interestingly, two months after transplantation, almost 20% of peripheral blood cells from the transplanted mice displayed a humanspecific CD45 immunophenotype with CD45+CD13+CD34+CD38+ cells. The analysis of peripheral blood smears also showed the typical human AML cell morphology with a larger nucleus and reduced cytoplasmic ratio. Therefore, the study dem onstrated that DEKNUP214 could transform human CD34+ progenitor cells and induced human AML in vivo. Gene profiling of this model revealed that several genes of HOX family (HOXA9, 10, B3, B4 and PBX3) were highly upregulated. In this AML model pathways involving KRAS, BRCA1 and ALK were significantly dysregulated [53] . Similar results were obtained in case of t(8;13) (p11;q12) chromosome translocation which led to ZM YM2FGFR1 chimeric kinase, characteristic for another AML subtype. Human CD34+ cells harboring ZMYM2 FGFR1 transplanted into immunecompromised mice developed myeloproliferative disease that progressed to AML. Mice displayed hepatosplenomegaly, hypercellular BM and a CD45 + CD34 + CD13+ immunophenotype [54] . Preclinical cancer research remains essential for the discovery and the development of new therapies in case of the most advanced cancers. Various cancer cell lines have been developed and used for the study of cancer but with a great disadvantage that they do not really reflect the behavior of the original cancer cells, due to the artificial nature of their culture conditions.
Patient derived xenografts -patient stem-cells derived xenografts
PDX models established by transplanting patient can cer cells into immunocompromised mice represent an important tool in cancer research. They have a great potential to offer important information on cancer bi ology and to guide the therapeutic approach. Unlike cell lines derived from primary tumors that might have lost their original characteristics due to a prolonged in vitro growth, PDX mouse models seemed to be able to overcome this issue [55, 56] . Many studies demonstrated that PDX models kept the most important features of the original tumor including histology, genomic pattern, cellular heterogeneity, and more important, drug resp onsiveness or personalized drug selection [57] . The development of PDX models of AML allows us to monitor in vivo the progression of the disease and to evaluate the efficacy of an experimental treatment on tumor growth using imaging techniques [58] . A first full study on the engraftment ability of a large cohort of AML samples in immunodeficient anim al models was published by Kennedy et al [59] who tra nsplanted BM or peripheral blood cells from 307 AML patients intrafemorally into sublethally irradiated NOD. SCID mice pretreated with an antiCD122 antibody. AML xenografts were obtained in 44% of cases, le ukemic engraftment being associated with a higher white cell count in peripheral blood (mean of 92 x 10 9 /L in engrafters vs 67 x 10 9 /L in nonengrafters, P = 0.01). Moreover, results showed that complete remission was achieved in only 51% of patients whose diagnostic samples established AML xenografts, compared to 80% of nonengrafting samples (P < 0.0001). As a conclusion, AML xenografting was successful when using samples from AML patients with aggressive di sease and with a poor response to standard induction therapy.
OVERCOMING CHALLENGES IN PATIENT-DERIVED XENOGRAFTS OF AML
Recent experiments are trying to improve mouse ex perimental models of AML, aiming to engraft with a higher success rate even less aggressive leukemia samples. Most of them are based on immunodeficient mice with humanized microenvironment created by injection of human mesenchymal stem cell (MSC) that provide a better niche for leukemic blast engraftment.
An interesting approach was that of Reinisch et al [60] , who used human MSC grafts injected subcutaneously in NSG mice to form a humanized microenvironment named "ossicles", in which they subsequently injected (8 wk later) human HSCs and AML blasts. The final aim was to analyze the engraftment capacity the resulting niche. After 610 wk, the "ossicles" showed human BMlike functions and morphology and allowed enhanced engraftment of primary patientderived AML.
A further attempt employed humanized niches based on genetically modified MSCs to express huIL3 and TPO. Carretta et al [61] implanted subcutaneously these human MSCs in ceramic scaffolds or Matrigel in NGS mice, and 6 to 8 wk later transplanted CD34+ enriched AML blasts in the ectopically engineered BM niches. The engraftment capacity was then compared with the one from nonengineered MSC niches. The results showed that leukemic blasts efficiently engrafted in both models with no significant differences. An unexpected result was that CD33+sorted myeloid clones from the animal model failed to selfrenew in secondary recipients, probably due to overexpressed IL3 and TPO cytokines from modified microenvironment that might have aff ected a proper selfrenewal of myeloid blasts. An important challenge for obtaining mouse models valuable as preclinical models is the capability of PDX cells to authentically mimic the heterogeneity of the initial disease. The xenograft mouse model of AML has been used mainly to study primary transplantation and further serial experiments were performed to verify selfrenewal competence or stability of gene expression profiles of engrafted cells. However, this model was rarely employed to investigate deeply AML biology or therapy [62] . Most of the published results re vealed that PDX cells resembled the primary samples in terms of gene expression profiles but subclonal profiles were often not reflecting the primary sample. Another important drawback was the inability of the most proposed models to sensitively and repetitively monitor disease progression or drug effects. These were determined at single time points by invasive procedures or post mortem. However, researchers tried to overcome these challenges by proposing a better control of PDX cells. This control aimed to check the pattern of alt erations in mutational or antigen expression possibly occurred during engraftment. For better monitoring disease progression or drug effects, recombinant lu ciferase enabled bioluminescence in vivo imaging has been proposed to facilitate in vivo monitoring of PDX AML cells as a quantitative, sensitive, reliable method for quantifying leukemia initiating cells [62] .
CONCLUSION
Mouse models were of tremendous importance for unde rstanding the molecular etiology of leukemia, proven to be valuable tools to facilitate preclinical in vivo studies.
Most of the studies verified that PDX models kept the most important features of the original tumor. However, mouse models should be controlled more carefully be fore and after xenotransplantation, especially in serial transplantation experiments, in order to ensure that the heterogeneity of the original sample is conserved and genetic drift is not modifying genetic, phenotypic or functional characteristics of the original disease.
Prospectively, advancements allowing repetitive, reliable, sensitive and fast studies, able to evaluate the efficacy of an experimental treatment in well genetically defined and heterogeneous subgroups of AML, will re present valuable tools to improve the individualized xenograft mouse model of AML and drastically reduce the number of mice to be used in these kind of experiments.
